Retreatment of gefitinib in patients with non-small-cell lung cancer who previously controlled to gefitinib: a single-arm, open-label, phase II study
Most patients with non-small-cell lung cancer (NSCLC) who initially respond to epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) eventually experience …
Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a …
S Watanabe, J Tanaka, T Ota, R Kondo, H Tanaka… - BMC cancer, 2011 - Springer
Background Gefitinib was the first epidermal growth factor receptor-tyrosine kinase inhibitor
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
(EGFR-TKI) approved for the treatment of advanced non-small cell lung cancer (NSCLC) …
Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer
H Yokouchi, K Yamazaki, I Kinoshita, J Konishi… - BMC cancer, 2007 - Springer
Background Gefitinib, an oral agent of epidermal growth factor receptor tyrosine kinase
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
inhibitor, has a certain efficacy against non-small cell lung cancer (NSCLC). Several …
Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania
ML Veronese, K Algazy, L Bearn, B Eaby… - Cancer …, 2005 - Taylor & Francis
Gefitinib (Iressa; AstraZeneca Pharmaceuticals, Wilmington, DE) is an oral epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
factor receptor tyrosine kinase inhibitor (EGFR-TKI) with favorable toxicity and antitumor …
Effect of gefitinib re-challenge to initial gefitinib responder with non-small cell lung cancer followed by chemotherapy
Y Tomizawa, Y Fujita, A Tamura, M Shirai, S Shibata… - Lung Cancer, 2010 - Elsevier
PURPOSE: We investigated the efficacy of gefitinib re-challenge for the patients who
responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter …
responded to initial treatment with gefitinib and acquired resistance to gefitinib thereafter …
Prospective study of gefitinib readministration after chemotherapy in patients with advanced non–small-cell lung cancer who previously responded to gefitinib
T Koizumi, T Agatsuma, K Ikegami, T Suzuki… - Clinical lung cancer, 2012 - Elsevier
Introduction Salvage treatment for acquired resistance to epidermal growth factor receptor
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
tyrosine kinase inhibitor in patients with non–small-cell lung cancer is a matter of clinical …
Phase II study of gefitinib readministration in patients with advanced non-small cell lung cancer and previous response to gefitinib
H Asahina, S Oizumi, A Inoue, I Kinoshita, T Ishida… - Oncology, 2011 - karger.com
Objective: Salvage treatment for acquired resistance to gefitinib has yet to be developed. We
conducted the first prospective phase II study of gefitinib readministration in previous …
conducted the first prospective phase II study of gefitinib readministration in previous …
Treatment after the failure of gefitinib in patients with advanced or recurrent non-small cell lung cancer
R Maruyama, H Wataya, T Seto, Y Ichinose - Anticancer research, 2009 - ar.iiarjournals.org
Background: The optimal treatment for patients with progressive non-small cell lung cancer
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …
who initially show a good response to gefitinib is unclear. Patients and Methods: This study …
Single agent gefitinib as first line therapy in patients with advanced non-small cell lung cancer: Washington University experience
A Kommareddy, MA Coplin, F Gao, D Behnken… - Lung Cancer, 2004 - Elsevier
Gefitinib has modest activity with an overall response rate of 11–18% in patients with
metastatic non-small cell lung cancer (NSCLC) who have had progressive disease following …
metastatic non-small cell lung cancer (NSCLC) who have had progressive disease following …
[HTML][HTML] Multicenter phase II trial of gefitinib first-line therapy followed by chemotherapy in advanced non-small-cell lung cancer (NSCLC): SAKK protocol 19/03
Background Gefitinib is active in patients with pretreated non-small-cell lung cancer
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …
(NSCLC). We evaluated the activity and toxicity of gefitinib first-line treatment in advanced …